Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
KamadaXTAE:KMDA -0.82%84 FCF Margin % is -2.79% as of Mar. 2026. GuruFocus rates XTAE:KMDA with a GF Score™ of 84/100 and a GF Value™ of ₪25.14 (Modestly Undervalued). Among 963 Drug Manufacturers companies, Kamada ranks better than 68.54% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Kamada's Free Cash Flow for the
three
months ended in Mar. 2026 was ₪-3.8 Mil. Kamada's Revenue for the
three
months ended in Mar. 2026 was ₪135.9 Mil. Therefore, Kamada's FCF Margin % for the quarter that ended in Mar. 2026 was -2.79%.
The historical data trend for Kamada's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTAE:KMDA vs ZTS, UTHR, VTRS: FCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kamada's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kamada FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kamada's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Kamada's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kamada (XTAE:KMDA) has a FCF Margin % of -2.79% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Kamada and its competitors. According to the industry distribution chart, Kamada ranks #303 out of 963 companies in the Drug Manufacturers industry, placing it in the top 31.5%.
Is Kamada's FCF Margin % too high?
Kamada's current FCF Margin % is -2.79%. Based on the distribution chart, Kamada ranks #303 out of 963 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Kamada has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kamada's FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Kamada ranks #303 out of 963 companies for FCF Margin %. This puts Kamada in the upper half of its industry. The industry median FCF Margin % is 2.58. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.58, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Kamada and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kamada's current FCF Margin % is -2.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kamada stock overvalued right now?
Based on GuruFocus' analysis, Kamada (XTAE:KMDA) is currently considered Modestly Undervalued. The stock's GF Value™ is ₪25.14, compared to a current price of ₪21.80 — trading 13.3% below its estimated fair value. The current FCF Margin % is -2.79%. Kamada's overall GF Score™ is 84/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Kamada (XTAE:KMDA), the current FCF Margin % is -2.79% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kamada (XTAE:KMDA) Overvalued in 2026?
Based on GuruFocus' analysis, Kamada stock appears to be undervalued.
The current stock price of ₪21.80 is trading 13.3% below its estimated GF Value™ of ₪25.14.
GuruFocus considers Kamada to be Modestly Undervalued.
Key valuation signals for XTAE:KMDA:
FCF Margin %: -2.79%
GF Value™: ₪25.14 vs. price of ₪21.80 (13.3% below fair value)
No single metric tells the full story. See the XTAE:KMDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
84GF Score
Get the complete analysis for XTAE:KMDA
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTAE:KMDA has been successfully added to your 
